Kerwin Medical Center

Dallas, Texas 75231

4 studies enrolling now · 21 studies all time

What they study most

Aggression, Agitation,Psychomotor, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer's Disease, Alzheimers Disease, Alzheimers Disease, Familial, Amyloid, Atypical Parkinsonism, Brain Diseases, Care Giving Burden, Central Nervous System Diseases

Studies at this site

• A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) — Recruiting now
• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Recruiting now
• Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies — Recruiting now
• Clinical Trial on Agitation in Alzheimer's Dementia — Recruiting now
• Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 — Running, not enrolling
• PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) — Running, not enrolling
• A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) — Running, not enrolling
• A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease — Completed
• A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease — Completed
• A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) — Completed
• AMX0035 and Progressive Supranuclear Palsy — Completed
• A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Running, not enrolling
• A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) — Running, not enrolling
• Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD) — Running, not enrolling
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) — Stopped early
• A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease — Stopped early
• A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) — Completed
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) — Stopped early
• Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) — Stopped early
• A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD — Completed